哈佛生物科学 2026年季度报告

☒Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period fromtoCommission file number 001-33957 HARVARD BIOSCIENCE, INC.(Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction ofIncorporation or organization) 84 October Hill Road, Holliston, Massachusetts 01746(Address of Principal Executive Offices, including zip code) (508) 893-8999(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S- T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 5, 2026, there were4,510,182 shares of the registrant’s common stock issued and outstanding. This information reflectsthe reverse stock split of the registrant’s common stock that became effective on March 13, 2026 and began trading on a post-splitadjusted basis on March 16, 2026. Table of Contents HARVARD BIOSCIENCE, INC. FORM 10-Q INDEX Item 1.Financial Statements (unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations2Condensed Consolidated Statements of Comprehensive Loss3Condensed Consolidated Statements of Stockholders' Equity4Condensed Consolidated Statements of Cash Flows5Notes to Condensed Unaudited Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures about Market Risk21Item 4.Controls and Procedures21PART II - OTHER INFORMATIONItem 1.Legal Proceedings22Item1A.Risk Factors22Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.22Item 3.Defaults Upon Senior Securities22Item 4.Mine Safety Disclosures23Item 5.Other Information23Item 6.Exhibits23SIGNATURES24 PART I. FINANCIAL INFORMATION HARVARD BIOSCIENCE, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited, in thousands, except share and per share data) See accompanying notes to condensed consolidated financial statements. HARVARD BIOSCIENCE, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited, in thousands, except per share data) HARVARD BIOSCIENCE, INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(Unaudited, in thousands) Three Months Ended March 31,20262025Net loss$(3,424)$(50,340)Other comprehensive income (loss), net of tax:Foreign currency translation adjustments(641)1,292Derivative instruments qualifying as cash flow hedges, net of tax of $-0--17Other comprehensive (loss) income(641)1,309Comprehensive loss$(4,065)$(49,031) HARVARD BIOSCIENCE, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited, in thousands)Accumulate See accompanying notes to condensed consolidated financial statements. HARVARD BIOSCIENCE, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited, in thousands) NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1.Basis of Presentation and Summary of Significant Accounting Policies The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the“Company”) as of March 31, 2026 and for the three months ended March 31, 2026 and 2025, have been prepared by the Companypursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnotedisclosures normally included in financial statements prepared in accordance w